Wall Street analysts predict that ClearPoint Neuro, Inc. (NASDAQ:CLPT) will post earnings of ($0.14) per share for the current quarter, Zacks reports. Two analysts have provided estimates for ClearPoint Neuro’s earnings, with estimates ranging from ($0.15) to ($0.13). ClearPoint Neuro posted earnings of ($0.08) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 75%. The business is scheduled to announce its next quarterly earnings results on Tuesday, November 10th.
According to Zacks, analysts expect that ClearPoint Neuro will report full year earnings of ($0.52) per share for the current fiscal year, with EPS estimates ranging from ($0.52) to ($0.51). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.51) per share, with EPS estimates ranging from ($0.69) to ($0.33). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow ClearPoint Neuro.
ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. ClearPoint Neuro had a negative net margin of 55.27% and a negative return on equity of 176.52%. The firm had revenue of $2.48 million for the quarter, compared to analysts’ expectations of $1.88 million.
ClearPoint Neuro Company Profile
ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies.
See Also: What is meant by holder of record?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.